Combined Drug Targeting of p53-dependent and -independent Pathways Depletes Myelofibrosis Hematopoietic Stem/Progenitor Cells

Current therapy for myelofibrosis (MF) results in a limited prolongation of patient survival. In order to improve treatment outcomes, we developed a strategy to effectively deplete MF hematopoietic stem/progenitor cells (HSPCs). In the present study, an imipridone, ONC201, was combined with RG7112,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Min, Xia, Lijuan, Elmansy, Nada, Clementelli, Cara, Tremblay, Douglas, Hoffman, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885407/
https://www.ncbi.nlm.nih.gov/pubmed/34642468
http://dx.doi.org/10.1038/s41375-021-01446-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885407/
https://www.ncbi.nlm.nih.gov/pubmed/34642468
http://dx.doi.org/10.1038/s41375-021-01446-4

Ejemplares similares